Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence
After High-Profile Setbacks In The Clinic
Executive Summary
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."